660-P: Greater Proportions of Subjects Achieved Composite Endpoints with Once-Weekly Semaglutide vs. Comparators in SUSTAIN Trials

Abstract

Achieving HbA1c targets, weight loss (WL) and systolic blood pressure (SBP) reductions lowers micro- and macrovascular risk in type 2 diabetes (T2D). In SUSTAIN clinical trials, once-weekly (OW) semaglutide, a glucagon-like peptide-1 analog, significantly reduced HbA1c and body weight (BW) and reduced SBP (except in SUSTAIN 8) vs. comparators. This post hoc analysis evaluated composites of these endpoints with semaglutide vs. comparators in SUSTAIN 1-5 and 7-10.Trials were analyzed individually to determine the proportion of subjects achieving composite endpoints A (HbA1c <7.0%, WL ≥5%, SBP reduction ≥5 mmHg) and B (HbA1c ≤6.5%, WL ≥10%, SBP reduction ≥5 mmHg). On-treatment-without-rescue-medication data were used.Across the trials, mean baseline HbA1c, BW and SBP ranges were 8.0-8.4%, 89.5-96.9 kg and 127.9-136.4 mmHg, respectively. Greater proportions of subjects achieved the composite endpoints with semaglutide vs. comparator (A: 12.4-19.1% [0.5 mg]; 18.9-36.7% [1.0 mg] vs. 0.8-15.7% [comparator]; B: 2.5-8.0% [0.5 mg]; 5.0-14.8% [1.0 mg] vs. 0.2-3.0% [comparator]; p<0.05 for both endpoints; Figure).Significantly greater proportions of subjects achieved clinically relevant composite endpoints with OW semaglutide vs. comparators, including more stringent endpoint of HbA1c ≤6.5% and WL ≥10%. These data may assist clinicians in their decision-making in T2D care.View largeDownload slideView largeDownload slide DisclosureP. Gæde: None. A. Catarig: Employee; Self; Novo Nordisk. K. M. Dungan: Advisory Panel; Self; Eli Lilly and Company, Tolerion, Inc., Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Elsevier, Novo Nordisk, Other Relationship; Self; UpToDate, Research Support; Self; Abbott, Sanofi-Aventis, Viacyte, Inc. C. Hindsberger: Consultant; Self; Novo Nordisk A/S, Stock/Shareholder; Self; Novo Nordisk A/S, Stock/Shareholder; Spouse/Partner; Novo Nordisk A/S. J. Øllgaard: Employee; Self; Novo Nordisk A/S. S. C. Bain: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Lilly Diabetes, Napp Pharmaceuticals, Novo Nordisk A/S, Sanofi, Consultant; Self; ADOCIA, Speaker’s Bureau; Self; Bayer AG, Medscape, WebMD LLC.FundingNovo Nordisk A/S